Several studies have shown that PD-L1 is highly expressed in GBM, and checkpoint blocking immunotherapy has shown positive results in a GBM mouse model, suggesting that immune checkpoints can be used in the treatment of GBM [15–17]. Here, CD274 is linked to glioblastoma.